PharmTech News

Articles

ProBioGen plans to develop and scale-up production of a biosimilar to the mAb cancer drug trastuzumab and will transfer the commercial manufacturing process to Indonesia’s government-owned Bio Farma.

ProBioGen and Bio Farma Plan Indonesian Production of Trastuzumab

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

According to a third-quarter earnings report, Pfizer’s vaccine business contributed nearly 14% to its total revenue.

Revenues from Pfizer’s Vaccine Business Increase

Biovest’s mAbVault provides supply-chain redundancy for antibodies that enables customers to lock in price-per-gram protein production.

Biovest Introduces Service to Guarantee mAb Supply

AstraZeneca and Lilly will evaluate the safety and efficacy of a range of additional combinations for solid tumors across both companies’ complementary portfolios.

AstraZeneca and Lilly Extend Immuno-Oncology Pact with New Combination Therapies

Athenex will build two facilities for high-potency, oncology API ingredients in Chongqing, China.

Athenex Expands API Manufacturing in China

The site is expected to become fully operational in 2017 and will produce approximately 40 million packs and 850 million tablets of some 30 innovative medicines every year.

AstraZeneca Opens New Manufacturing Facility in Russia

Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera in the Middle East and North America.

Hikma Signs Licensing, Distribution, and Supply Agreement with Basilea Pharmaceutica International for Antibiotic Zevtera

Senator McCaskill deemed J. Michael Pearson’s response letter on drug pricing “inadequate.”

Valeant Addresses Questions on Pricing; Receives Subpoenas

Cell Therapy Catapult will provide manufacturing scale-up services to enable Asterias’ future clinical trials and commercial supply for Asterias’ allogeneic dendritic cell immunotherapy, AST-VAC2.

Cell Therapy Catapult to Develop Process for Asterias Biotherapeutics

BASF will develop a higher-purity version of poloxamer 188 for Mast Therapeutics, a biopharmaceutical company.

Bio/Pharma News